PH27531A - Stabilized leukocyte interferons - Google Patents

Stabilized leukocyte interferons

Info

Publication number
PH27531A
PH27531A PH41267A PH41267A PH27531A PH 27531 A PH27531 A PH 27531A PH 41267 A PH41267 A PH 41267A PH 41267 A PH41267 A PH 41267A PH 27531 A PH27531 A PH 27531A
Authority
PH
Philippines
Prior art keywords
leukocyte interferons
stabilized
stabilized leukocyte
interferons
leukocyte
Prior art date
Application number
PH41267A
Inventor
Alberto Dr Ferro
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH27531A publication Critical patent/PH27531A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH41267A 1989-09-28 1990-09-26 Stabilized leukocyte interferons PH27531A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (1)

Publication Number Publication Date
PH27531A true PH27531A (en) 1993-08-18

Family

ID=4257630

Family Applications (1)

Application Number Title Priority Date Filing Date
PH41267A PH27531A (en) 1989-09-28 1990-09-26 Stabilized leukocyte interferons

Country Status (26)

Country Link
EP (1) EP0420049B1 (en)
JP (1) JPH03130232A (en)
KR (1) KR910005886A (en)
CN (1) CN1050503A (en)
AR (1) AR244551A1 (en)
AT (1) ATE92334T1 (en)
AU (1) AU636653B2 (en)
CA (1) CA2024046A1 (en)
CZ (1) CZ277712B6 (en)
DD (1) DD298054A5 (en)
DE (1) DE59002183D1 (en)
FI (1) FI904756A7 (en)
HU (1) HU205555B (en)
IE (1) IE903479A1 (en)
IL (1) IL95769A0 (en)
IS (1) IS3631A7 (en)
MC (1) MC2149A1 (en)
MX (1) MX22522A (en)
MY (1) MY106615A (en)
NO (1) NO904218L (en)
NZ (1) NZ235153A (en)
PH (1) PH27531A (en)
PT (1) PT95454A (en)
RU (1) RU2008017C1 (en)
YU (1) YU184090A (en)
ZA (1) ZA907579B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
DK0920329T3 (en) * 1996-05-09 2003-01-27 Feronpatent Ltd Stabilization of interferons in aqueous solution with gum arabic
AU730020B2 (en) * 1997-05-09 2001-02-22 Feronpatent Limited Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets
JP3643034B2 (en) * 1998-03-26 2005-04-27 シェーリング コーポレイション Formulation for protection of PEG-interferon alpha conjugate
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CN1175901C (en) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 Stable water solution of interferon
DE602005022895D1 (en) 2004-08-12 2010-09-23 Schering Corp STABLE PEGYLATED INTERFERON FORMULATION
DE102004048379A1 (en) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Spring element made of sputtered shape memory alloy
CU23432B6 (en) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (en) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd Purifying method of interferon
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
MA20647A1 (en) * 1985-03-25 1986-10-01 Schering Corp STABLE COMPOSITIONS BASED ON INTERFERON-GAMMA
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
HUT56284A (en) 1991-08-28
NO904218D0 (en) 1990-09-27
HU906021D0 (en) 1991-03-28
PT95454A (en) 1991-05-22
IL95769A0 (en) 1991-06-30
AU636653B2 (en) 1993-05-06
EP0420049A1 (en) 1991-04-03
DD298054A5 (en) 1992-02-06
YU184090A (en) 1992-09-07
CN1050503A (en) 1991-04-10
IE903479A1 (en) 1991-04-10
CZ277712B6 (en) 1993-03-17
ZA907579B (en) 1991-06-26
MC2149A1 (en) 1992-03-10
ATE92334T1 (en) 1993-08-15
MY106615A (en) 1995-06-30
NZ235153A (en) 1993-03-26
AU6309890A (en) 1991-04-11
CA2024046A1 (en) 1991-03-29
AR244551A1 (en) 1993-11-30
DE59002183D1 (en) 1993-09-09
CS432890A3 (en) 1992-12-16
FI904756A0 (en) 1990-09-27
HU205555B (en) 1992-05-28
IS3631A7 (en) 1991-03-29
KR910005886A (en) 1991-04-27
FI904756A7 (en) 1991-03-29
NO904218L (en) 1991-04-02
MX22522A (en) 1993-10-01
JPH03130232A (en) 1991-06-04
RU2008017C1 (en) 1994-02-28
EP0420049B1 (en) 1993-08-04

Similar Documents

Publication Publication Date Title
GB8923188D0 (en) Conveyors
IL95769A0 (en) Stabilized leukocyte interferons
GB9024710D0 (en) Syringe
KR930007460B1 (en) Servo-positioning circuit
GB8911158D0 (en) Antiviral pyridazinamines
GB8903386D0 (en) Conveyors
EP0409350A3 (en) Certain glyoxyl-cyclohexendiones
GB8906928D0 (en) Conveyors
GB8615353D0 (en) Interferon
IL93808A0 (en) Carrying-handle attachment
GB9014515D0 (en) Syringe
PL286706A1 (en) Conveying
EP0419411A3 (en) Additional alkanophenones
GB8814773D0 (en) Electromagnetic components
AU105209S (en) Extrusion
GB9000152D0 (en) Double-display function calculator
GB8928962D0 (en) Antiviral combinations and compounds therefor
GB8924629D0 (en) Antiviral substances
GB8922397D0 (en) Antiviral pentofuranosides
AU105891S (en) Continuous wheel-belt
GB8914160D0 (en) Guard arrangement
IE893507L (en) Modified interleukin-2
ZA896964B (en) Fans
IL95596A0 (en) Insulin requirement determination
GB8903306D0 (en) Cases